Rosenblum Silverman Sutton’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Rosenblum Silverman Sutton’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5,790	Closed	-$309K	–	69
2017 Q4	$309K	Hold	5,790	–	–	0.11%	65
2017 Q3	$345K	Buy	5,790 +1,125	+24%	+$68.1K	0.13%	60
2017 Q2	$368K	Buy	4,665 +400	+9%	+$32.7K	0.15%	59
2017 Q1	$354K	Sell	4,265 -25	-0.6%	-$1.86K	0.15%	59
2016 Q4	$340K	Sell	4,290 -725	-14%	-$52.7K	0.16%	58
2016 Q3	$351K	Buy	+5,015	New	+$278K	0.16%	60
2015 Q4	$1.98M	Hold	22,375	–	–	0.91%	41
2015 Q3	$1.66M	Buy	22,375 +8,435	+61%	+$702K	0.79%	42
2015 Q2	$1.13M	Buy	+13,940	New	+$908K	0.45%	53

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Rosenblum Silverman Sutton's EGRX Position: Q1 2018 in Review

Rosenblum Silverman Sutton sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2018, closing a stake of 5,790 shares — an estimated $309K sold.

Rosenblum Silverman Sutton first reported a position in EGRX in Q2 2015 and held it in 9 quarters. The position peaked at $1.98M in Q4 2015. 174 funds tracked by Wall St. Rank hold EGRX as of Q1 2018.

Rosenblum Silverman Sutton reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Rosenblum Silverman Sutton sold 5,790 Eagle Pharmaceuticals, Inc. shares in Q1 2018, an estimated $309K.
Rosenblum Silverman Sutton first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 9 quarters.
Rosenblum Silverman Sutton's Eagle Pharmaceuticals, Inc. position peaked at $1.98M in Q4 2015.
174 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2018.

Based on Rosenblum Silverman Sutton's 13F filing for Q1 2018, filed 10 May 2018.